E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10013538 |
E.1.2 | Term | Diverticulitis |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the time to recurrence of diverticulitis between each of 3 doses of SPD476 (1.2g/day QD, 2.4g/day QD, and 4.8g/day QD) and placebo QD in subjects who have had at least one previous attack of diverticulitis. Recurrence of diverticulitis is defined as: • A positive spiral computerised axial tomography (CT) scan for diverticulitis as evidenced by, at a minimum, fat stranding (with or without bowel wall thickening >5mm) OR • Surgical intervention for diverticular disease |
|
E.2.2 | Secondary objectives of the trial |
• To compare the proportion of subjects without recurrence of diverticulitis between each of 3 doses of SPD476 (1.2g/day QD, 2.4g/day QD, and 4.8g/day QD) and placebo QD at weeks 26, 52, and 104 • To compare the proportion of subjects with recurrence of complicated versus uncomplicated diverticulitis between each of 3 doses of SPD476 (1.2g/day QD, 2.4g/day QD, and 4.8g/day QD) and placebo QD • To compare the proportion of subjects requiring surgical intervention for diverticular disease between each of 3 doses of SPD476 (1.2g/day QD, 2.4g/day QD, and 4.8g/day QD) and placebo QD • To compare Quality of Life (QoL) using the EQ5D and Health Utilities Index (HUI2) questionnaires between treatment groups at Baseline, Weeks 16, 52, 78, and 104 between each of 3 doses of SPD476 (1.2g/day QD, 2.4g/day QD, and 4.8g/day QD) and placebo QD • To assess the safety and tolerability of SPD476 1.2g/day QD, 2.4g/day QD, and 4.8g/day QD for the duration of the treatment period |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Study Title: A follow-on, prospective outcomes sub-study to summarise healthcare resource utilisation and quality of life in subjects who withdraw study medication due to diverticulitis from SPD476-314, version 2 - 16 May 2008
Primary: To summarise healthcare resource utilisation in subjects who withdraw due to diverticulitis from the SPD476-314 study. Recurrence of diverticulitis is defined as: • A positive spiral computerised axial tomography (CT) scan for diverticulitis as evidenced by, at a minimum, fat stranding (with or without bowel wall thickening >5mm) OR • Surgical intervention for diverticulitis disease Secondary: • To summarise quality of life in subjects who withdraw due to recurrence of diverticulitis |
|
E.3 | Principal inclusion criteria |
1. Written, signed, and dated informed consent to participate in the study must be given by the subject, in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E6 and applicable regulations, before completing any study-related procedures 2. Male and female subjects ≥18 years of age 3. If female of childbearing potential (FOCP), has demonstrated a negative beta HCG (human chorionic gonadotropin) serum pregnancy test, and agrees to comply with any applicable contraceptive requirements of the protocol 4. At least one documented attack of acute diverticulitis in the previous 24 months that has clinically resolved without colonic resection. Documentation must include a verifiable report confirming acute diverticulitis (examples include CT scan, magnetic resonance imaging (MRI) scan, ultrasound, endoscopy of the sigmoid colon, or barium enema) 5. Confirmation of diverticulosis via endoscopic evaluation of the sigmoid colon, with at least three diverticula noted. The presence of mild erythema and loss of vascularity (oedema) is acceptable, whereas frank ulceration and evidence of ischaemia is not 6. White blood cell (WBC) count within central laboratory normal reference ranges 7. Polymorphonuclear leukocyte (PMN) level within central laboratory normal reference ranges 8. Subject and Investigator must agree that participation in this study is in the best interest of the subject |
|
E.4 | Principal exclusion criteria |
1. Subjects who have had an attack of diverticulitis and/or continue to exhibit signs and symptoms of diverticulitis within 6 weeks prior to and up to Baseline 2. Previous colorectal surgery, including surgical intervention for diverticular disease, (with the exception of haemorrhoidectomy, colonic removal of polyps, and appendectomy) 3. Clinically relevant gross extraluminal pathology as shown by CT scan 4. Right sided diverticulosis only 5. Active peptic ulcer disease 6. History of or current presence of inflammatory bowel disease (IBD) 7. Subjects with active irritable bowel syndrome (IBS) requiring ongoing medication 8. Active GI bleeding, except for positive faecal occult blood test (FOBT) in the stool 9. Active or recent history of endometriosis or dysmenorrhoea within 6 months prior to Baseline 10. Allergy or hypersensitivity to mesalazine (5-ASA) or aspirin 11. Subjects who are unwilling or unable to undergo a CT scan or have a known or suspected allergy to all radiologic contrast agents 12. Subjects must not have used another investigational product within 30 days prior to Baseline 13. Within 14 days of Baseline, use of prebiotic, probiotic, or 5-ASA medications, as well as drugs active at the 5HT-receptor (e.g., tegaserod, alosetron, metaclopramide), or anti-spasmotic agents 14. Any current or historical use of biologics (anti-TNF agents) 15. Use of immunomodulators (e.g., azathioprine, 6-mercaptopurine) within 6 weeks prior to Baseline 16. Use of systemic or rectal steroids within 6 weeks of Baseline. Use of inhaled or nasal steroids is acceptable 17. Subjects who have conditions requiring regular and ongoing use of anti-inflammatory drugs, including NSAIDs, such as aspirin, COX-2 inhibitors, or ibuprofen. Use of aspirin (≤325mg/day) taken for cardiac prophylaxis is acceptable 18. Subjects with clinically relevant moderate or severe renal or hepatic impairment are contraindicated with mesalazine products 19. Current or relevant previous disease that could affect the colon, action, absorption, or disposition of the investigational product, or clinical or laboratory assessments 20. Any history of malignancy, except for basal cell skin cancer, cervical carcinoma in-situ, or carcinoma insitu in a colonoscopically removed polyp 21. Subjects with a history of alcohol or other substance abuse within the previous year 22. Females who are lactating 23. Current or relevant history of serious, severe, or unstable (acute of progressive) physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully complete the study, or any condition that presents undue risk from the study medication or procedures 24. Subjects who have previously been screened for or enrolled into this study and subsequently withdrawn |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary: To compare the time to recurrence of diverticulitis between each of 3 doses of SPD476 (1.2g/day QD, 2.4g/day QD, and 4.8g/day QD) and placebo QD in subjects who have had at least one previous attack of diverticulitis
Recurrence of diverticulitis is defined as: • A positive spiral computerised axial tomography (CT) scan for diverticulitis as evidenced by, at a minimum, fat stranding (with or without bowel wall thickening >5mm) OR • Surgical intervention for diverticular disease.
Secondary: • To compare the proportion of subjects without recurrence of diverticulitis between each of 3 doses of SPD476 (1.2g/day QD, 2.4g/day QD, and 4.8g/day QD) and placebo QD at Weeks 26, 52, and 104 • To compare the proportion of subjects with recurrence of complicated versus uncomplicated diverticulitis between each of 3 doses of SPD476 (1.2g/day QD, 2.4g/day QD, and 4.8g/day QD) and placebo QD • To compare the proportion of subjects requiring surgical intervention for diverticular disease between each of 3 doses of SPD476 (1.2g/day QD, 2.4g/day QD, and 4.8g/day QD) and placebo QD • To compare Quality of Life (QoL) using the EQ5D and Health Utilities Index (HUI2) questionnaires between treatment groups at Baseline, Weeks 16, 52, 78, and 104 between each of 3 doses of SPD476 (1.2g/day QD, 2.4g/day QD, and 4.8g/day QD) and placebo QD • To assess the safety and tolerability of SPD476 1.2g/day QD, 2.4g/day QD, and 4.8g/day QD for the duration of the treatment period.
Tertiary: • To compare lower endoscopy assessments of the sigmoid area between treatment groups at Screening and Week 104 and/or Withdrawal of Treatment visits • To compare histology of biopsy samples between treatment groups at Screening and Week 104 and/or Withdrawal of Treatment visits. • To compare the change in WBC count from Baseline between treatment groups at all study visits • To compare the proportion of subjects with a shift to the left (1% increase in bands) between treatment groups at all study visits • To compare the change in C-Reactive Protein (CRP) from Baseline between treatment groups at all study visits. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 45 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 4 |